Given the relatively smaller reduction in body weight (9.4%) in the SELECT trial compared to previous RCTs: 14.9% in STEP1 (BMI 37.86.7 kg/m 2 ) [16] and 13.2% STEP6 (BMI 31.9 kg/m 2 ) [49], pleiotropic effects of semaglutide may contribute to the overall CV risk reduction [25,37]
While Novo Nordisk and Eli Lilly both have promising GLP-1 pipelines and anticipate multiple drug launches over the next five years, several other big pharma companies are also investing heavily in GLP-1 drugs in a bid to grab a slice of the pie, primarily through the acquisition of biotech developers [FIGURE THREE]
These include a relative or absolute increase in glucagon secretion from alpha cells of the pancreas, elevated serum free fatty-acid concentrations, an impaired incretin effect (e.g., decreased secretion of glucagon-like peptide-1 [GLP-1]), enhanced renal reabsorption of glucose, and dysregulation of appetite control via decreased neurotransmitter response in the brain
doi: 10.2337/dc11-s227 8 BrownJCPedersonRAJorpesEMuttV
Schedule an initial visit to discuss the best treatment plan for you
Remove thoroughly
